Kaskela Law is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company’s long-term investors.
Recently a securities fraud complaint was filed against DexCom on behalf of certain investors who purchased shares of the company’s stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during the Wrongdoing Period, DexCom and certain of the company’s senior executive officers made a series of materially false and misleading statements to investors about DexCom’s central product – a device it sold to diabetes patients to monitor their blood sugar – the G7 “continuous glucose monitoring” system (“CGM”).
As detailed in the complaint, the defendants are alleged to have “misleadingly touted the G7 as the ‘most accurate CGM cleared by the FDA’ even though they had secretly switched out a critical component of the device without FDA approval and knew from their own testing that the resulting device ‘was worse’ than the original in ‘every accuracy metric.’” When the truth was revealed in a series of partial corrective disclosures – including a stunning revenue miss caused by disappointing sales of the faulty G7 and a scathing warning letter from the FDA detailing the company’s adulteration of the G7 – DexCom lost half of its market capitalization, and the company’s long-term investors suffered significant investment losses.
The investigation seeks to determine whether the members of DexCom’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.
DexCom shareholders who have owned the company’s shares since at least January 8, 2024 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, via email at [email protected], or by filling out the form on this page.